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Abstract
Introduction: Osteoporosis is a syndrome of excessive skeletal fragility characterized by the loss of mass and
deterioration of microarchitecture in bone. Single use of aspirin or adipose-derived stromal cells (ASCs) has been
recognized recently to be effective against osteoporosis. The goal of the study was to evaluate the osteogenic
effects of the co-administration of aspirin and allogeneic rat adipose-derived stromal cells (rASCs) on ovariectomized
(OVX)-induced bone loss in rats. The underlying mechanisms were investigated in vitro and in vivo.
Methods: Firstly, allogeneic rASCs were isolated and cultured, and the conditioned medium (CM) from the
maintenance of rASCs was collected. Secondly, the OVX rats were administrated CM, rASCs, aspirin (ASP) or rASCs
+ ASP, respectively. Twelve weeks later, the anti-inflammatory and osteogenic effects were assessed by micro-CT,
undecalcified histological sections, dynamic histomorphometric analyses and serologic assays for biochemical
markers. Finally, a Transwell migration assay in vitro and cell-trafficking analyses in vivo were used to explore the
effects of aspirin on rASC migration.
Results: Systemic administration of aspirin and rASCs attenuated OVX-induced bone loss better than single use
of aspirin or ASCs (p < 0.05, respectively). Next, we analyzed the underlying mechanisms of the anti-inflammatory
and chemotactic abilities of aspirin. Aspirin suppressed serum levels of the pro-inflammatory cytokines on tumor
necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), and the anti-inflammatory ability was positively associated with
bone morphometry. Also, aspirin exhibited excellent chemotactic effects in vitro and accelerated the homing of
allogeneic rASCs into bone marrow during early in vivo stages.
Conclusions: Co-administered aspirin and allogeneic ASCs can partially reverse OVX-induced bone loss in rats.
This effect appears to be mediated by the anti-inflammatory and chemotactic abilities of aspirin.
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Introduction
Osteoporosis is a syndrome of excessive skeletal fragility
characterized by loss of the mass and deterioration of the
microarchitecture of bone, which leads to fragility frac-
tures [1]. The prevalence of osteoporosis has increased
rapidly among the elderly as life expectancy has increased
in industrialized countries [2].
Two major pharmacologic approaches to the treatment
of osteoporosis are anabolic agents such as parathyroid
hormone [3, 4] (which stimulate bone formation) or anti-
resorptive agents such as bisphosphonates, calcitonin,
raloxifene, and estrogen (which inhibit bone resorption)
[5, 6]. These therapies have been shown to increase bone
mineral density (BMD) and reduce the risk of fractures,
but long-term safety and efficacy are ongoing concerns
[7]. Thus, new safe and effective modalities are desired to
ameliorate osteoporotic conditions.
Stem-cell therapy has been investigated for the repair
and regeneration of damaged tissue in various conditions
(e.g., myocardial ischemia [8, 9], stroke [10, 11], diabetes
mellitus [12, 13], and cartilage/bone defects [14–16])
owing to the potential for multi-lineage differentiation of
stem cells. Bone marrow (BM) has been most commonly
used as a source of mesenchymal stem cells (MSCs), but
the number and capacity for multi-lineage differentiation
decline with age or health of donors [17–19]. Moreover,
obtaining BM is an invasive procedure that can cause
complications such as pain, bleeding, and infection.
To circumvent these limitations, adipose-derived stro-
mal cells (ASCs) have been used recently as alternative
sources of MSCs. ASCs have the following advantages
over other sources of MSCs: multi-lineage MSCs have
similar potential to that of bone marrow-derived mesen-
chymal stem cells (BMMSCs); ease of harvesting; and
abundant sources [20–23]. Furthermore, by avoiding
difficulties in obtaining sufficient numbers of autologous
stem cells and decreased osteogenic potential of ASCs as
a result of donor aging [24], ASCs from allogeneic donors
could constitute a valuable alternative source of stem cells
for therapeutic use because ASCs have superior immuno-
modulatory effects than other sources of MSCs. Taken
together, ASCs may be a better source of stem cells for
the treatment of osteoporosis [25, 26].
Aspirin is a widely used non-steroidal anti-inflammatory
drug. Epidemiologic studies have suggested that aspirin
might have a moderate beneficial effect on BMD in post-
menopausal women [27]. Recently, Liu et al. reported that
implantation of BMMSCs/hydrogel/aspirin resulted in
improvement of bone generation in calvarial defects by
improving the osteogenesis of, and by inhibiting the
apoptosis of, BMMSCs [28]. Moreover, several lines of
evidence have suggested that aspirin can inhibit osteo-
clastogenesis and improve osteogenesis by suppression
of expression of pro-inflammatory cytokines, inhibition
of activity of cyclooxygenase 1 and 2, and prostaglandin-
E2, and up-regulation of telomerase activity in BMMSCs
[29–32]. Thus, we speculated that aspirin could favor stem
cell-mediated bone regeneration by affecting multiple
biological pathways.
Hu et al. demonstrated that aspirin can induce angio-
genesis by promoting migration of endothelial progeni-
tor cells [33]. Brunelli et al. also reported that HCT
1026 (a nitric oxide-donating agent with nonsteroidal
anti-inflammatory activity) enhanced the therapeutic
efficacy of arterially delivered donor stem cells by in-
creasing their ability to migrate and reconstitute muscle
fibers [34]. In the above-mentioned studies, aspirin or
other nonsteroidal anti-inflammatory agents improved
angiogenesis or reconstituted muscle fibers by promot-
ing the migration of stem (progenitor) cells to the target
organ. Therefore, we hypothesized that aspirin can im-
prove osteogenesis (at least in part) by enhancing homing
of stem cells into BM.
We wished to evaluate the effects of co-administration
of aspirin and allogeneic rat adipose-derived stromal
cells (rASCs) on ovariectomized (OVX)-induced bone
loss in rats, and investigated the underlying mechanism
of these effects in vitro and in vivo.
Methods
Ethical approval of the study protocol
All animal experiments were approved by the Animal Care
and Use Committee of Peking University Health Science
Center (approval number: LA2014233; Beijing, China).
Isolation and maintenance of rASCs and preparation of
conditioned medium
All materials were purchased from Sigma–Aldrich (Saint
Louis, MO, USA) unless stated otherwise. For rASCs,
Lewis rats were euthanized at eight weeks of age by CO2
asphyxiation according to standard protocols. Visceral
fat pads were minced and digested by type-I collagenase,
filtered through cell strainers (pore size, 100 μm; Biolo-
gix, Lenexa, KS, USA) and centrifuged for 10 minutes at
380 × g at room temperature. Cells were cultivated in
maintenance medium [Dulbecco’s modified Eagle’s
medium (DMEM) containing 10 % fetal bovine serum
(FBS), 100 U/mL penicillin G, and 100 mg/mL strepto-
mycin] at 37 °C in an atmosphere of 5 % CO2. rASCs of
passage 3–5 were used and all cell-based experiments
were repeated at least three times.
To prepare the conditioned medium (CM) of rASCs,
cells were detached upon reaching 80 % confluence in a
10-cm2 dish and cultured for 12 h by DMEM containing
2 % FBS. Next, rASCs were cultured by a serum-free
DMEM for 12 h and the supernatant was collected and
sterilized by passage through a filter (pore size, 0.22 μm).
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Animals and administration procedure
Rats were allowed free access to water and a maintenance
diet in a 12-h light–dark cycle at a room temperature of
21 ± 2 °C. Rats were housed in groups of ≤5.
Eight-week-old female F344 rats (n = 70) were ob-
tained from Vital River Inc. (Beijing, China). Bilateral
OVX or sham operation was undertaken by standard
methods under general anesthesia using pentobarbital
sodium (50 mg/kg, i.p.).
Four weeks after surgery, rats were assigned ran-
domly into seven groups of ten: (1) sham rats were
injected with vehicle (Sham group); (2) OVX rats were
injected with vehicle (OVX); (3) OVX rats were injected
with zoledronate (ZOL); (4) OVX rats were injected
with allogeneic rASCs CM (ASC CM); (5) OVX rats
were injected with allogeneic rASCs (ASC), (6) OVX
rats were given a gavage of aspirin (ASP), (7) OVX rats
were injected with rASCs and given a gavage of aspirin
(ASC + ASP) .
On days 1, 2, 8, and 9, 200 μL of CM (total of
800 μL; ASC CM group) or 1.5 × 106 allogeneic rASCs
in 200 μL of DMEM (total of 6 × 106 cells; ASC and
ASC + ASP groups) were injected into the lateral tail
vein. Then, 100 mg/kg body weight of aspirin in 2 mL
of physiologic (0.9 %) saline (1 % DMSO assisted
solubilization) was given by gavage every day of the
total study period in ASP and ASC + ASP groups. In
sham and OVX groups, DMEM and physiologic saline
were administered each time. As a positive control,
zoledronate (100 μg/kg, s.c.) was administered on day-
1 and day-8 in the ZOL group.
Twelve weeks later, after euthanasia, the right tibia
from each animal was dissected free from soft tissue
thoroughly and fixed in 10 % neutral-buffered formalin.
Subsequently, it was used for micro-computed tomog-
raphy (CT) and histological slicing.
Micro-CT analyses
To evaluate the mass and microarchitecture in bone
among the seven groups, micro-CT was undertaken
using an Inveon MM system (Siemens, Munich,
Germany). Images were acquired at an effective pixel
size of 8.82 μm, voltage of 80 kV, current of 500 μA
and exposure time of 1,500 ms in each of the 360 rota-
tional steps. Parameters were calculated using an
Inveon Research Workplace (Siemens) as follows: bone
volume/total volume (BV/TV), bone surface area/bone
volume (BS/BV), trabecular thickness (Tb.Th), trabecu-
lar number (Tb.N), trabecular separation (Tb.Sp) and
BMD in the trabecular region (1–2 mm distal to the
proximal epiphysis) according to guidelines set by the
American Society for Bone and Mineral Research [35].
Slicing of undecalcified bones and dynamic
histomorphometric analyses
Rats were injected with alizarin-3-methyliminodiacetic
acid (30 mg/kg body weight, i.p.) ten days before euthan-
asia and calcein (20 mg/kg body weight, i.p.) three days
before. The tibia was fixed as described above and dehy-
drated in ethanol followed by embedding in destabilized
methyl methacrylate resin. Next, sections were ground
and polished to 40–60 μm by an EXAKT precision cutting
and grinding system (EXAKT Apparatebau, Hamburg,
Germany) and stained (hemotoxylin and eosin). Dynamic
histomorphometry was undertaken using Bioquant soft-
ware (BioQuant, San Diego, CA, USA).
Assay for biochemical markers
For detection of biochemical markers of bone turnover
and pro-inflammatory cytokines, blood samples were ac-
quired from the aorta ventralis upon euthanasia. Serum
was separated and stored at −80 °C. Serum levels of pro-
collagen 1 N-terminal peptide (P1NP), bone alkaline
phosphatase (ALP), and tartrate-resistant acid phosphat-
ase (TRAP) were measured using the relevant enzyme-
linked immunoassay (ELISA) kits (IDS, Frankfurt,
Germany). Serum levels of calcium were measured using
a Plasma Emission Spectrometer (iCAP 6000; Thermo
Fisher Scientific, Waltham, MA, USA). Serum levels of
tumor necrosis factor (TNF)-α and interferon (IFN)-γ
were measured using the relevant ELISA kits
(eBioscience, San Diego, CA, USA). Samples were mea-
sured in duplicate (at least).
Cell-migration assay in vitro and in vivo
To explore the effects of aspirin on migration of rASCs,
a transwell migration assay in vitro and cell-trafficking
analyses in vivo were used.
For the transwell migration assay, 1 × 105 cells from pas-
sage 4 were loaded into the upper chamber of a 24-well
transwell plate (pore size, 8 μm; Corning, Corning, NY,
USA) and 600 μL DMEM containing different concentra-
tions of aspirin added to the lower chamber. Twenty-four
hours later, cells on the upper surface of the membranes
were removed with a cotton swab. Cells that had migrated
to the lower surface of the membrane were fixed with
10 % neutral-buffered formalin and stained for 15 min
with 0.5 % crystal violet. The number of cells that had mi-
grated into the lower chamber was counted twice in five
randomly selected microscopic fields (at × 400 magnifica-
tion) per filter by blind evaluations by two independent
assessors. All aspirin concentrations were repeated at least
three times.
For cell-trafficking analyses, a parallel assay using fluor-
escent dye-labeled cell injection was used. Forty 12-week-
old F344 rats were divided into two groups of twenty
animals four weeks after surgery: (1) OVX rats were given
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a gavage of vehicle (OVX-Vehicle); and (2) OVX rats were
given a gavage of aspirin (OVX-ASP). A total of 100 mg/kg
aspirin in 2 mL of physiologic saline was given by gavage
on each day of the total study period. After one week of
gavage, allogeneic rASCs were labeled with 5 μM CM-DiL
fluorescent dye (CellTracker™ CM-DiL; Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions for adherent cells. A total of 1.5 × 106 CM-
DIL-labeled allogeneic rASCs from Lewis rats in
200 μL of DMEM were injected into F344 rats after
four weeks of OVX (n = 4, at each time point of then
group). Rats were euthanized at 6, 12, 24, 48, and 72 h
after cell injection. BM cells from the femur were obtained
as described previously [36] and analyzed for CM-DiL-
positive cells (104 cells per sample) with LSRFortessa™
(BD Biosciences, Franklin Lakes, NJ, USA).
Statistical analysis
Data are shown as the mean ± standard deviation. SPSS
v16.0 (IBM, Armonk, NY, USA) was used for statistical
analyses. Independent two-tailed Student’s t-test or one-
way analysis of variance (ANOVA) with post hoc least
significant difference (LSD) were performed, and p-values
less than 0.05 were considered significant.
Results
Radiologic and histologic evaluation of the mass and
microarchitecture of bone
To assess the mass and microarchitecture of bone,
BMD and bone morphometry were carried out using
micro-CT (Fig. 1a) and the results are shown in Table 1.
For BMD, micro-CT analyses of the proximal tibia
ex vivo demonstrated that the OVX groups (OVX, ASC
CM, ASC, ASP, and ASC + ASP groups, n = 50) exhib-
ited significantly less BMD compared with the sham
group except the ZOL group (p < 0.001). Interestingly,
the BMD of the ASC CM group increased significantly
compared with the OVX and ASC groups (OVX group
p = 0.012, ASC group p = 0.032). However, inconsistent
with BMD results, the ASC CM group showed a poor
effect upon bone microarchitecture among the treat-
ment groups (ASC CM, ASC, ASP, and ASC + ASP
groups). The ASC CM group had a dramatically de-
creased BV/TV compared to the ASC + ASP group (p =
0.001) and a dramatically decreased Tb.Th compared
with the other treatment groups (ASC group p = 0.005,
ASP group p = 0.033, ASC + ASP group p < 0.001). The
ASC CM group had significantly increased BS/BV com-
pared with the other treatment groups (ASC group, p =
0.009; ASP group, p = 0.045; ASC +ASP group, p < 0.001).
The ASC +ASP group had a significantly increased BV/
TV, Tb.N, and Tb.Sp compared with the ASC group and
ASP group (for the ASC group and ASP group, respect-
ively, BV/TV: p = 0.006 and p = 0.002; Tb.N: p = 0.006 and
p = 0.004; Tb.Sp: p = 0.020 and p = 0.013).
To confirm radiologic evaluation of tibias, analyses of
slices of hard tissues were undertaken and the results of
bone morphometry from histology were similar to those
of the micro-CT (data not shown) (Fig. 1b).
Dynamic histomorphometric analyses
Consistent with the analyses of bone microarchitecture,
dynamic histomorphometric analyses also revealed sig-
nificant increases in the bone formation rate (BFR) in
Fig. 1 Representative images of changes in bone microarchitecture in rats. Tibias of F344 rats were dissected and evaluated ex vivo by micro-CT
(a) and slicing of undecalcified tissues (H & E staining); (b) eight weeks after treatment
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the ASC + ASP group compared with the OVX, ASC
CM, and ASP groups (OVX group, p < 0.001; ASP group,
p < 0.001; ASC CM group, p = 0.006) (Fig. 2). However,
the BFR of the ASP group was reduced significantly
compared with the ASC group (p = 0.006). The BFR of
the OVX groups (OVX, ASC CM, ASC, ASP, and ASC
+ ASP groups, n = 50) was decreased significantly com-
pared with the sham group (p < 0.001). The ZOL group
showed irregular fluorescence and calculation of the BFR
was difficult because osteoclast-directed bone resorption
(which is usually coupled with bone formation) was inhib-
ited (data not shown).
Serological assessment of the formation and resorption
of bone
Data from the ELISA of P1NP, ALP, and TRAP from
each group are shown in Fig. 3. As expected, serum
levels of P1NP from the OVX groups (OVX, ZOL, ASC
CM, ASC, ASP, and ASC + ASP groups, n = 60), a
marker of bone formation, were significantly lower than
those of the sham group (OVX, ZOL, ASC CM, and
ASP groups, p < 0.001; ASC group, p = 0.001; ASC + ASP
group, p = 0.011). In accordance with bone histomorpho-
metric analyses, serum levels of P1NP were dramatically
higher in the ASC + ASP group than in OVX, ASC CM,
and ASP groups (OVX group, p < 0.001; ASC CM group,
p = 0.027; ASP group, p = 0.007). Also, P1NP levels in
the ASP group were decreased significantly compared
with those of the ASC group (p =0.022) (Fig. 3a).
Similar to the data from the ELISA for P1NP, serum
levels of ALP from the OVX, ZOL, ASC, and ASP
groups (n = 40) were significantly lower than those of
the sham group (OVX group, p = 0.002; ZOL group, p <
0.001; ASC group, p = 0.018; and ASP group, p = 0.003).
Moreover, ALP levels in the ASC + ASP group dramatic-
ally increased compared with the OVX, ZOL, and ASP
groups (OVX group, p = 0.016; ZOL group, p = 0.001;
ASP group, p = 0.018) (Fig. 3b).
Moreover, serum levels of TRAP (a marker of bone
resorption) were significantly lower in the sham group
than in the OVX, ASC CM, ASC, ASP, and ASC + ASP
groups (OVX, ASC CM, ASC and ASP groups, p < 0.001;
ASC +ASP group, p = 0.001). Notably, owing to the anti-
resorption effect of zoledronate in bone, TRAP levels in
the ZOL group were decreased significantly compared
with the OVX, ASC CM, ASC, and ASP groups (OVX,
ASC CM, and ASP groups, p < 0.001; ASC group, p =
0.001). Serum levels of TRAP in the ASC +ASP group
Table 1 Mineral density and histomorphometry of tibias in the seven groups of rats
Groups Sham OVX ZOL ASC CM ASC ASP ASC + ASP
BMD (g/cm3) 1.791 ± 0.048 1.445 ± 0.031 a 1.969 ± 0.069 a,b 1.497 ± 0.031 a,b,c 1.457 ± 0.045 a,c,d 1.466 ± 0.034 a,c 1.470 ± 0.024 a,c
BV/TV (%) 44.009 ± 2.432 23.676 ± 2.848 a 87.026 ± 2.388 a,b 29.216 ± 2.435 a,b,c 30.202 ± 4.569 a,b,c 29.378 ± 3.394 a,b,c 34.521 ± 1.965 a,b,c,d,e,f
BS/BV (mm−1) 33.857 ± 2.247 37.474 ± 1.611a 12.362 ± 2.142 a,b 35.788 ± 1.108 c 33.214 ± 2.372 b,c,d 33.784 ± 2.210 b,c,d 32.162 ± 1.642 b,c,d
Tb.Th (mm) 0.059 ± 0.003 0.053 ± 0.002 a 0.156 ± 0.003 a,b 0.056 ± 0.002 a,c 0.060 ± 0.004 b,c,d 0.059 ± 0.004 b,c,d 0.062 ± 0.003 b,c,d
Tb.N (mm−1) 7.376 ± 0.204 4.427 ± 0.473 a 8.008 ± 0.252 a,b 5.223 ± 0.400 a,b,c 4.979 ± 0.540 a,b,c 4.934 ± 0.359 a,b,c 5.551 ± 0.410 a,b,c,e,f
Tb.Sp (mm) 0.077 ± 0.008 0.174 ± 0.022 a 0.026 ± 0.007 a,b 0.137 ± 0.015 a,b,c 0.143 ± 0.025 a,b,c 0.144 ± 0.018 a,b,c 0.119 ± 0.012 a,b,c,e,f
Parameters of bone mineral density (BMD) and microarchitecture (BV/TV, BS/BV, Tb.Th, Tb.N, Tb.Sp) were measured in the trabecular bone of the proximal tibia
(1–2 mm distal to the proximal physis) using micro-CT. Data are the mean ± SD, n = 70
OVX ovariectomized, ZOL zoledronate, ASC adipose-derived stromal cells, CM conditioned medium, ASP aspirin, BV/TV bone volume/total volume, BS/BV bone sur-
face area/bone volume, Tb.Th trabecular thickness, Tb.N trabecular number, Tb.Sp trabecular separation
ap < 0.05 vs. Sham, bp < 0.05 vs. OVX, cp < 0.05 vs. ZOL, dp < 0.05 vs. ASC CM, ep < 0.05 vs. ASC, fp < 0.05 vs. ASP
Fig. 2 Dynamic histomorphometric analyses of rat tibias. a Representative fluorescence images obtained from tibias after double labeling with
alizarin red and calcein. Scale bar = 50 μm. b Bone formation rate (BFR) was measured from the tibia using Bio-quant software. Data are the
mean ± SD. *p < 0.05 vs. Sham, #p < 0.05 vs. OVX, &p < 0.05 vs. ASC CM, %p < 0.05 vs. ASC, black triangle p < 0.05 vs. ASP. OVX ovariectomized,
ASC adipose-derived stromal cells, ASP aspirin
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were reduced significantly compared with those in the
OVX, ASC CM, and ASP groups (OVX group, p = 0.004;
ASC CM group, p = 0.038; ASP group, p = 0.003). How-
ever, there was no significant difference among the OVX,
ASC CM, ASC, and ASP groups (Fig. 3c). These findings
suggest that systemic administration of rASCs, ASC CM,
or aspirin primarily affected bone formation and osteo-
blastic activity, and was also associated with bone re-
sorption (especially in the ASC + ASP group).
Serological assessment of calcium
ELISAs suggested that serum levels of calcium in the
OVX, ZOL, ASC CM, and ASP groups (OVX, ZOL,
ASC CM groups, p < 0.001; ASP group, p = 0.003) de-
creased significantly compared with those in the sham
group (Fig. 4). Calcium levels in the serum of rats in
the ASC + ASP and ASC groups were comparable with
those of the sham group. Serum levels of calcium in the
ASC + ASP group increased significantly compared with
those in the OVX, ZOL, ASC CM, and ASP groups
(OVX, ZOL, and ASC CM groups, p < 0.001; ASP group,
p = 0.002). However, serum levels of calcium decreased
significantly in the ASC CM group compared with those
in the other treatment groups (ASC, ASP, and ASC +ASP
groups) (p < 0.001, respectively).
Serological assessment of pro-inflammatory cytokines
(TNF-α and IFN-γ)
Serum levels of TNF-α and IFN-γ among the seven
groups are shown in Fig. 5. As expected, serum levels of
TNF-α and IFN-γ were increased significantly in the
OVX, ZOL, ASC CM, and ASC groups (TNF-α: OVX and
ASC CM groups, p < 0.001; ZOL group, p = 0.001; ASC
group, p = 0.002; IFN-γ: OVX and ZOL groups, p < 0.001;
ASC CM group, p = 0.001; ASC group p = 0.036) com-
pared with the sham group. Consistent with the results of
bone microarchitecture, serum levels of TNF-α and IFN-γ
were decreased significantly in the ASC + ASP group
compared with the OVX, ZOL, ASC CM, and ASC
groups (TNF-α: OVX group, p = 0.001; ZOL group, p =
0.020; ASC CM group, p = 0.012; ASC group, p = 0.038;
IFN-γ: OVX and ZOL groups, p < 0.001; ASC CM
group, p = 0.001; ASC group, p = 0.030). Moreover,
serum levels of TNF-α and IFN-γ in the ASP group
were significantly lower than those in the OVX, ZOL,
and ASC CM groups (TNF-α: OVX group, p = 0.003;
ZOL group, p = 0.045; ASC CM group, p = 0.032; IFN-
γ: OVX group, p < 0.001; ZOL group, p = 0.001; ASC
CM group, p = 0.014).
Effect of aspirin on chemotactic ability in vitro
The effect of aspirin on chemotactic ability in vitro is
shown in Fig. 6. The ability of rASCs to migrate at as-
pirin concentrations of 0.001, 0.01, 0.1, and 1 mM was
Fig. 3 Serum levels of biochemical markers of bone turnover. Serum levels of P1NP (a) and ALP (b) (marker of bone formation), and TRAP 5b
(marker of bone resorption) (c) eight weeks after treatment. Data are the mean ± SD of experiments carried out in triplicate. *p < 0.05 vs. Sham,
#p < 0.05 vs. OVX, $p < 0.05 vs. ZOL, &p < 0.05 vs. ASC CM, %p < 0.05 vs. ASC, black triangle p < 0.05 vs. ASP. P1NP, procollagen 1 N-terminal
peptide, ALP alkaline phosphatase, TRAP, tartrate-resistant acid phosphatase, OVX ovariectomized, ZOL zoledronate, ASC adipose-derived stromal
cells, ASP aspirin
Fig. 4 Serum levels of calcium eight weeks after treatment. Data are
the mean ± SD.*p < 0.05 vs. Sham, #p < 0.05 vs. OVX, $p < 0.05 vs.
ZOL, &p < 0.05 vs. ASC CM, black triangle p < 0.05 vs. ASP. ALP
alkaline phosphatase, OVX ovariectomized, ZOL zoledronate, ASC CM
Adipose-derived stromal cells conditioned medium, ASP aspirin
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enhanced significantly compared with that in the con-
trol group (0.001 mM and 0.01 mM, p < 0.001; 0.1 mM,
p = 0.016; 1 mM, p = 0.022). At aspirin concentrations
of 0.001 mM and 0.01 mM, cell migration was 135 %
and 137 % higher than that of the control group. More-
over, significant increases were observed in the 0.001-
mM and 0.01-mM groups compared with 0.1-mM
(0.001 mM, p = 0.004; 0.01 mM, p = 0.003) and 1-mM
groups (0.001 mM, p = 0.003; 0.01 mM, p = 0.002).
However, the cell-migration ratio in the 0.0001-mM
group was not increased significantly compared with
that in the control group (p > 0.05). A significant differ-
ence between 0.1-mM and 1-mM groups was not
observed.
Effect of aspirin on homing of rASCs in vivo
The effect of aspirin on homing of rASCs by cell-
trafficking assays in vivo is shown as a curve of the ra-
tio of rASCs/bone marrow stromal cells (BMSCs) in
the BM at different time points in Fig. 7. At 6, 12, and
24 h after treatment, the ratio of rASCs/BMSCs in the
OVX-ASP group was significantly greater than that in
the OVX-Vehicle group (33.77 ± 3.49 % vs. 26.9 ± 1.56 %
at 6 h, p = 0.036; 60.37 % ± 0.78 % vs. 49.7 % ± 5.32 % at
12 h, p = 0.027; 63.27 % ± 4.11 % vs. 49.9 % ± 6.58 % at
24 h, p = 0.041). The difference in the ratio of homing of
rASCs increased gradually from 6 h to 24 h between the
OVX-ASP group and OVX-Vehicle group, and reached a
maximum at 24 h. At 48 h and 72 h, the ratio of rASCs/
BMSCs in the OVX-ASP group was higher than that in
the OVX-Vehicle group, but this difference was not
significant. In the OVX-ASP group, the ratio of rASCs/
BMSCs increased rapidly before 24 h after treatment and
gradually declined until 72 h.
Discussion
In the present study, we demonstrated for the first time
that the co-administration of aspirin and allogeneic rASCs
partially prevented OVX-induced bone loss in OVX rats.
We also confirmed that the effects of co-administered as-
pirin and allogeneic rASCs can attenuate bone loss more
effectively than either one alone. Nevertheless, the single
administration of aspirin or allogeneic rASCs (and even
rASCs CM) also partially prevented bone loss in
Fig. 5 Serum levels of TNF-α and IFN-γ by ELISA eight weeks after treatment. Serum levels of TNF-α (a) and IFN-γ (b) among the seven groups. Data
are the mean ± SD of experiments undertaken in triplicate. *p < 0.05 vs. Sham, #p < 0.05 vs. OVX, $p < 0.05 vs. ZOL, &p < 0.05 vs. ASC CM, %p < 0.05 vs.
ASC. OVX ovariectomized, ZOL zoledronate, ASC CM adipose-derived stromal cells conditioned medium
Fig. 6 The in vitro chemotactic ability of aspirin by transwell assays. a Representative images of ASC migration at different concentrations of aspirin.
Scale bar = 50 μm. b The number of migrating cells at different concentrations of aspirin. Data are the mean ± SD of experiments undertaken in
triplicate. *p < 0.05 vs. control, #p < 0.05 vs. 0.0001 mM, $p < 0.05 vs. 0.001 mM, &p < 0.05 vs. 0.01 mM. ASC adipose-derived stromal cells
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comparison with the OVX control group. To fully explore
the underlying mechanism of this co-operation, a combin-
ation of in vitro and in vivo experiments was carried out.
We found that aspirin decreased serum levels of the
pro-inflammatory cytokines TNF-α and IFN-γ markedly.
Also, aspirin enhanced the chemotactic ability of rASCs
in vitro and accelerated homing of rASCs into BM in
vivo. These results suggest that aspirin has comprehen-
sive anti-inflammatory effects and promotes homing of
rASCs, which might be associated with attenuating
OVX-induced bone loss.
Anti-inflammatory effect of aspirin for bone regeneration
We found that aspirin significantly suppressed serum
levels of the pro-inflammatory cytokines TNF-α and IFN-
γ, which is in accordance with the findings of previously
reported studies [28, 37]. Meanwhile, the aspirin groups
(ASP and ASC +ASP groups) showed partially prevented
bone loss in OVX rats. Hence, we speculated that TNF-α
and IFN-γ may play a role in bone metabolism.
Firstly, several recent lines of evidence have supported
the hypothesis that IFN-γ or TNF-α accelerated osteo-
clastogenesis through T-cell immunity [38–41]. Studies
have shown that TNF-α (which is derived from activated
T cells as a result of OVX) augments macrophage
colony-stimulating factor (M-CSF)-induced and receptor
activator of nuclear factor-kappa B ligand (RANKL)-in-
duced osteoclastogenesis via the TNF-α receptor p55
when estrogen deficiency induces bone loss [38, 39].
Cenci et al. discovered that IFN-γ enhances by the up-
regulated expression of class-II transactivator located in
antigen-presenting cells (APC) and T lymphocytes in
OVX mice, resulting in enhanced antigen presentation
by macrophages, as well as enhanced T cell activation
and lifespan [40]. In this research, the serum levels of
TNF-α and IFN-γ in the OVX group were highest
among all seven groups, which also supports the above-
mentioned hypothesis. In addition, Gao et al. demon-
strated that IFN-γ indirectly promotes bone resorption by
multiple pathways (T cell activation and T cell secretion of
RANKL and TNF-α), but blunts osteoclast formation
through the direct targeting of osteoclast precursors.
However, under conditions of estrogen deficiency, infec-
tion and inflammation, the net balance of these two
opposing factors is biased toward bone resorption [41]. In
summary, co-operation of TNF-α and IFN-γ enhances the
proliferation and activation of T cells, and further
augments M-CSF-induced and RANKL-induced osteo-
clastogenesis. Our findings have demonstrated that the
levels of TRAP, a marker of bone resorption, in the ASC
+ASP group significantly decreased compared with those
in the OVX group, which is consistent with the results of
Fig. 7 Effect of aspirin on homing of rASCs by cell-trafficking assays in vivo. BM cells were flushed 6, 12, 24, 48, and 72 h after injection of
CM-DiL-labeled cells in the lateral tail vein and primary culture carried out. Thereafter, numbers of CM-DiL-positive cells were measured by
flow cytometry. The percentage of rASCs/BMSCs in the BM at different time points (a) and representative images of flow cytometry (b) are
shown. Data are the mean ± SD. *p < 0.05 vs. OVX-vehicle at 6 h, #p < 0.05 vs. OVX-vehicle at 12 h, $p < 0.05 vs. OVX-vehicle at 24 h. rASCs
rat adipose-derived stromal cells, BM bone marrow, CM conditioned medium, BMSCs bone marrow stromal cells, OVX ovariectomized.
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the above-mentioned studies. However, the level of TRAP
in the ASP group only reduced slightly compared with the
OVX group. This finding appeared to be inconsistent with
the observation that TNF-α and IFN-γ were suppressed
by aspirin. We conjectured that perhaps a small amount
of DMSO (1 % DMSO for aspirin solubilization) pro-
moted osteoclast differentiation [42] in the OVX model
and attenuated the inhibition of osteoclastogenesis. In
addition, Zhang et al. [43] showed that aspirin inhibits
osteoclast differentiation and bone resorption in a dose-
dependent manner, whereby low-dose aspirin has a weak
effect on osteoclast inhibition. In this study, we only
administered low-dose aspirin to the rats, equivalent to
15.87 mg/kg/d aspirin for humans, as calculated by the
relative body surface area between rats and humans [44].
Therefore, we determined that aspirin alone did not sig-
nificantly decrease TRAP levels compared to the OVX
groups as a probable consequence of the combination of
low-dose aspirin and DMSO.
Secondly, TNF-α and IFN-γ promoted the apoptosis of
BMMSCs and osteoblasts. Liu et al. demonstrated that
TNF-α and IFN-γ synergistically enhance BMMSC
apoptosis by the inhibition of the TNFR2/NFκB pathway
and Fas internalization, and inhibit BMMSC-mediated
bone formation [28]. More recently, Wang et al. showed
that TNF-α and IFN-γ synergistically downregulate
expression of FAS ligand in osteoblast progenitors and
reduce the ability to induce osteoclast apoptosis by oste-
oblasts [45].
Taken together, the above-described studies and the
results from the present study suggest that aspirin sup-
pressed levels of pro-inflammatory cytokines, such as
TNF-α and IFN-γ, and partially prevented bone loss,
which may be associated with decreasing osteoclasto-
genesis and inhibiting the apoptosis of BMMSCs and
osteoblasts. The mechanisms involved in aspirin and
bone loss will be the subject of future studies.
Chemotactic effects of aspirin on bone regeneration in
vitro and in vivo
The original intention of the present study was to use
aspirin as an anti-inflammatory agent to attenuate bone
loss in OVX rats. Interestingly, we found that aspirin
(0.001 mM–1 mM) increased the migration of rASCs in
vitro. Reports of the effects of aspirin on the migration
and homing of adipose-derived stem cells are lacking.
Hu et al. reported that low-dose aspirin promoted the
migration and adhesion of endothelial progenitor cells
due to the vasculoprotective benefits of aspirin [33]. The
results of the present study are consistent with those
studies. However, Chen et al. hypothesized that aspirin
decreases the proliferative, migratory, and adhesive ef-
fects of endothelial progenitor cells at higher concentra-
tions (1 mM–10 mM) [46]. These divergent views might
have resulted from the aspirin dose, variations in type
and/or species of cells, as well as the in vitro or in vivo
assays we employed.
Also, Brunelli et al. reported that HCT 1026 (an agent
with nonsteroidal anti-inflammatory activity) significantly
enhanced the engrafting to muscle of mesoangioblasts, a
type of stem cell shown to be effective in correcting gen-
etic defects of muscle. Interestingly, the increased homing
of mesoangioblasts to muscle has been shown to be ac-
companied by a concomitant reduction of their number in
the relevant filter organs (liver, lung, kidney, and spleen)
[34]. These findings regarding enhanced stem cell homing
by a nonsteroidal anti-inflammatory agent in vivo are
similar to our current results, although the underlying
mechanisms have not yet been explained. Although we
have not provided histological evidence as to why aspirin
promoted homing to the BM rather than elsewhere, the in
vivo and in vitro cell migration induced by aspirin de-
tected by both FCM and the transwell assays validated this
finding. It may be that the ability of aspirin to induce cell
migration is not specific for bone, and other organs or
tissues may also benefit. However, the bone will indeed
benefit if the aspirin induces rASCs to home to bone. In
future studies, we will use more specific methods to inves-
tigate the mechanism of stem cell homing.
Osteogenesis upon co-administration of aspirin and allo-
geneic ASCs in OVX rats
The single administration of aspirin, allogeneic rASCs
or rASCs CM resulted in partial osteogenesis. However,
co-administration of aspirin and allogeneic ASCs had
better effects upon bone regeneration. With regard to
the co-administration effects of aspirin and rASCs, as-
pirin improved the osteogenic microenvironment of
rASCs by suppressing expression of pro-inflammatory
cytokines and accelerating homing of rASCs, but allo-
geneic rASCs constitute an abundant source of stem
cells for therapeutic use and have excellent immunosup-
pressive and immunomodulatory properties [47, 48]. In
accordance with our conclusions, Liu Y et al. reported that
implantation of BMMSCs/hydrogel/aspirin resulted in im-
provement of bone generation in calvarial defects [28].
Taken together, the co-administration of aspirin and stem
cells appears to be a feasible strategy to promote stem
cell-mediated bone regeneration. However, young rASCs
were administered in this research, which have better
osteogenic effects than aged rASCs [49]. Moreover, the
more long-term osteogenic effects of young rASCs were
not studied. Next, we will study the long-term osteogenic
effects of administering young rASCs. Recently, Yan et al.
[50] reported that 5-azacytidine improves the osteo-
genic differentiation potential of aged ASCs by DNA
demethylation, which may indicate a useful area of fur-
ther investigation.
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Interestingly, we observed that the CM of allogeneic
rASCs also partially prevented OVX-induced bone loss
in rats and resulted in a higher BMD than that in the
ASC + ASP group. In support of our hypothesis, Mirsaidi
et al. showed that the osteogenic potential of human
BMSCs cultured with homogeneous ASC-CM dramatic-
ally increased compared with that of BMSCs cultured
with BMSC-CM [51]. Sun et al. discovered that in vitro,
treatment with ASC-CM enhanced osteogenic differenti-
ation in stromal cells and pre-osteoblasts [52]. Jee et al.
demonstrated that the CM of human umbilical cord
blood-derived mesenchymal stem cells preserved BMD
and improved trabecular parameters comparable with
that of the OVX group and appeared to be mediated by
a paracrine mechanism rather than direct engraftment
of MSCs [6]. Moreover, Banas et al. reported that MSCs
from adipose tissue produced significantly more im-
munosuppressive IL-1RA than BMMSCs; also IL-1RA
was a robust anti-inflammatory cytokine and inhibited
the binding of IL-1α and IL-1β [48].
Conclusions
We demonstrated that the systematic administration of
aspirin and allogeneic ASCs attenuated bone loss more
effectively than either one alone in OVX rats. Also, as-
pirin plays a key part in bone regeneration owing to its
anti-inflammatory and chemotactic abilities. The results
of our study will shed more light on the potential use of
aspirin and allogeneic ASCs in the prevention/treatment
of osteoporosis.
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